Viatris Inc (VTRS) Company Profile & Statistics

Viatris Inc
VTRS
(Nasdaq - US)
Closed
9.70
+0.09 (+0.88%)
in:usd•As of: Dec 06, 2023 15:59 UTC -5
Open
9.66
High
9.79
Low
9.63

About Viatris Inc

CEO

Michael Goettler

Headquarters

1000 mylan boulevard

canonsburg, pa 15317, united states

Auditor

DELOITTE & TOUCHE LLP

Employees

37,000

Share Holders

108,736

Website

https://www.viatris.com/en

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.

Viatris Inc Statistics

Valuation Measures

Market Capitalization ²	11.63B
Enterprise Value	30.35B
Enterprise Value/EBITDA (ttm)	7.62
Price to Earnings Ratio (ttm)	3.23
Price to Book (mrq)	0.56
Price to Sales (ttm)	0.75
Price to Cash (ytd)	1.65

Profitability

Gross Margin (ttm)	39.55%
Operating Margin (ttm)	23.37%
Profit Margin (ttm)	11.82%
Return on Equity (ttm)	17.27%
Return on Invested Capital (ttm)	4.53%
Return on Assets (ttm)	7.35%

Income Statement

Revenue (ttm)	15.47B
Revenue Per Share (ttm)	12.89
Gross Profit (ttm)	6.12B
EBITDA (ttm)³	3.99B
Net Income Avi to Common (ttm)	1.83B
Diluted EPS (ttm)	1.51

Share Statistics

Beta (5Y Monthly)	1.14
52-Week Change	-6.71%
S&P500 52-Week Change	15.43%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	1.20B
Dividend Yield	4.96%
Float ⁴	1.20B
% Held by Insiders	0.26%
% Held by Institutions	76.69%

Balance Sheet

Total Cash (mrq)	1.31B
Total Cash Per Share (mrq)	1.09
Total Debt (mrq)	20.03B
Total Debt/Equity (mrq)	96.00%
Current Ratio (mrq)	1.60%
Quick Ratio (mrq)	1.06%
Book Value Per Share (mrq)	17.39

Cash Flow

Operating Cash Flow Per Share (ytd)	1.92
Free Cash Flow (ytd)	2.17B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Viatris Inc

Trade With A Regulated Broker